Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.
Article Details
- CitationCopy to clipboard
Mosley JF 2nd, Smith L, Everton E, Fellner C
Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.
P T. 2015 Jul;40(7):451-62.
- PubMed ID
- 26185406 [ View in PubMed]
- Abstract
Sodium-glucose linked transporter 2 inhibitors limit the reabsorption of glucose from glomerular filtrate in the kidneys, reducing blood glucose levels in patients with type- 2 diabetes. This article is meant to evaluate this class of medications for clinicians.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Canagliflozin Cytochrome P450 3A4 Protein Humans UnknownSubstrateDetails